June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Evaluate of visual acuity in patients with diabetic macular edema treated with different anti-VEGF
Author Affiliations & Notes
  • Leonardo Pinheiro Teixeira
    Instituto de Olhos de Goiania, Teresina, Brazil
  • Mayara Martins Abrahao
    Instituto de Olhos de Goiania, Teresina, Brazil
  • Joao J Nassaralla
    Instituto de Olhos de Goiania, Teresina, Brazil
  • Footnotes
    Commercial Relationships   Leonardo Pinheiro Teixeira, None; Mayara Martins Abrahao, None; Joao Nassaralla, None
  • Footnotes
    Support  NONE
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1921. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Leonardo Pinheiro Teixeira, Mayara Martins Abrahao, Joao J Nassaralla; Evaluate of visual acuity in patients with diabetic macular edema treated with different anti-VEGF. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1921.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose :

To evaluate visual acuity after treatment of diabetic macular edema from patients stratified randomly into two groups in which one received ranibizumab and one received aflibercept.

Methods : This is a randomized clinical trial of patients treated in retina sector of Goiânia Institute of Eyes. Patients were diagnosed with non-proliferative or proliferative diabetic retinopathy associated with clinically significant diabetic macular edema justifying treatment with anti-VEGF. These were stratified into two groups in a randomized manner, in which one received alibercept 0.05 ml and the other ranibizumab 0.05 ml and subsequent visual acuity assessment being subjected to descriptive statistical analysis related to improvement, stability or worsening of visual acuity after the application of these different medications at days five and thirty after treatment.

Results : Eighteen eyes of 16 patients diagnosed with diabetic retinopathy in which there were no other diseases that justified the appearance of macular edema were evaluated. Among the selected 9 were male and 7 female. With the evaluation through the stratification already cited in the methodology after the fifth day of application of aflibercept, an improvement in visual acuity of about one line was already observed on the Snellen table, which increased to two lines in the evaluation of the thirtieth day Post intravitreal application; In the group receiving ranibizumab an improvement in visual acuity was observed for about a line that remained until the thirtieth day after application.

Conclusions : Compared with data in the literature, it was observed that aflibercept, besides having a longer lasting effect related to the reduction of diabetic macular edema according to studies related to optical coherence tomography, was also more efficient in the partial and long-term recovery of acuity Visual evaluation of the evaluated patients.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×